



(11) **EP 1 530 592 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Bibliography INID code(s) 84**

(51) Int Cl.:  
**C07K 14/74** <sup>(2006.01)</sup> **C07K 14/78** <sup>(2006.01)</sup>  
**C12N 15/62** <sup>(2006.01)</sup> **C12N 15/12** <sup>(2006.01)</sup>  
**A61K 38/17** <sup>(2006.01)</sup> **G01N 33/68** <sup>(2006.01)</sup>

(48) Corrigendum issued on:  
**25.03.2009 Bulletin 2009/13**

(86) International application number:  
**PCT/EP2003/009056**

(45) Date of publication and mention  
of the grant of the patent:  
**17.12.2008 Bulletin 2008/51**

(87) International publication number:  
**WO 2004/018520 (04.03.2004 Gazette 2004/10)**

(21) Application number: **03792325.7**

(22) Date of filing: **14.08.2003**

(54) **CHIMERIC MHC PROTEIN AND OLIGOMER THEREOF**

CHIMÄRES MHC-PROTEIN UND OLIGOMER DAVON  
PROTEINE CHIMERIQUE MHC ET SON OLIGOMERE

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GR HU  
IE IT LI LU MC NL PT RO SE SI SK TR**

(74) Representative: **Vossius & Partner**  
**Siebertstraße 4**  
**81675 München (DE)**

(30) Priority: **21.08.2002 GB 0219459**

(56) References cited:  
**WO-A-98/06749** **WO-A-99/42597**  
**WO-A-02/055992** **US-A1- 2002 082 411**

(43) Date of publication of application:  
**18.05.2005 Bulletin 2005/20**

(73) Proprietor: **Prolimmune Limited**  
**Oxford OX4 4GA (GB)**

(72) Inventors:  
• **SCHWABE, Nikolai, Franz, Gregor**  
**Oxford OX2 6BP (GB)**  
• **CHENG-CHOO TAN, Linda**  
**Oxford OX2 6BP (GB)**  
• **NAPPER, Catherine, Elizabeth**  
**Coggs, Whitney OX28 3UD (GB)**  
• **FRY, Jeremy, William**  
**Nuneham Courtney OX44 9PQ (GB)**  
• **PANG, Susan**  
**Lincoln LN2 2ES (GB)**  
• **SPOONER, Rachel, Kate**  
**Oxford OX3 0RU (GB)**

- **MÜLLER K M ET AL: "Protein fusions to coiled-coil domains." METHODS IN ENZYMOLOGY. UNITED STATES 2000, vol. 328, 2000, pages 261-282, XP008025980 ISSN: 0076-6879**
- **HOLLER N ET AL: "Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 237, no. 1-2, April 2000 (2000-04), pages 159-173, XP004192503 ISSN: 0022-1759 cited in the application**
- **TERSKIKH ALEXEY V ET AL: "Peptabody: A new type of high avidity binding protein" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 94, no. 5, 1997, pages 1663-1668, XP002147182 ISSN: 0027-8424**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 530 592 B8**